Journal of Clinical Oncology
Articles in this Issue
Rare histologic subtypes of triple-negative breast cancer: The impact of immunotherapy on outcomes for metastatic disease.
1120 Background: The addition of immunotherapy (IO) to chemotherapy (chemo) has significantly improved survival for patien...
Health-related quality of life (HRQOL) with pembrolizumab or observation for high-risk muscle-invasive urothelial carcinoma after surgery: Results from the AMBASSADOR randomized trial (Alliance A031501).
4513 Background: The AMBASSADOR trial (NCT03244381) showed that in patients with high-risk muscle-invasive urothelial carc...
A phase 1 first-in-human study of BGM-2121 in patients with advanced solid tumors.
TPS3172 Background: Parathyroid hormone-related protein (PTHrP) is a hormone frequently overexpressed in tumors such as pa...
Trends in disability-adjusted life years (DALY) from colorectal cancer in Germany: A lesson to be learned?
e22543 Background: The incidence and prevalence of colorectal cancer (CRC) is on the rise globally and consequently Disabi...
Lung-MAP S1800E: A randomized phase II/III study of docetaxel and ramucirumab with or without cemiplimab for patients previously treated with platinum-based chemotherapy and immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC).
TPS8669 Background: Integration of immunotherapy into first line systemic therapy for patients with metastatic NSCLC has l...
Failure-to-rescue after major complications in endometrial cancer: A National Inpatient analysis (NIS, 2016–2023).
e17637 Background: Although endometrial cancer is often considered low risk, postoperative outcomes may be driven more by...
A clinical study of a prototype DAA/TAA vaccine targeting MUC1 for immune interception and prevention in ductal carcinoma in situ.
TPS2699 Background: Hypoglycosylated tumor MUC1 is a transmembrane glycoprotein, recognized by human T-cells and antibodie...
Combining SBRT with GM-CSF and Peg-IFNα to induce abscopal effects in previously treated patients with metastatic thymic tumors: A single-institution, phase II trial.
8121 Background: After the failure of multi-line treatment, patients with metastatic thymic tumors have a poor prognosis a...
Cervical cancer patient outcomes in a safety-net healthcare system.
e17514 Background: Cervical cancer is largely a preventable cancer. Although cervical cancer rates are decreasing in the U...
Spino-RT: A multicenter, randomized controlled phase III study of adjuvant radiotherapy versus surveillance in patients with cutaneous squamous cell carcinoma (cSCC) at high risk of recurrence.
TPS9614 Background: cSCC is the second most common skin cancer, predominantly affecting elderly individuals. Most cSCCs ar...
Scalable knowledge distillation for thyroid cancer diagnosis: ResNet-based ultrasound classification with global deployment feasibility.
e20013 Background: Thyroid nodules are highly prevalent, while thyroid cancer accounts for 7–15% of cases, most commonly p...
Safety and clinical impact of totally implantable venous access ports during trabectedin therapy in advanced L-type sarcomas: A multicenter SEPSaC-01 analysis.
e23564 Background: Totally implantable venous access ports (TIVAPs) are routinely used to secure long-term central venous...
Circulating tumor DNA (ctDNA) monitoring of high-risk breast cancer patients: A retrospective descriptive analysis in a community setting.
e12606 Background: Circulating tumor (ct)DNA testing has emerged as a key prognostic biomarker for disease recurrence in b...
Lanreotide for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in a Korean population: A multicenter prospective observational study (AIM-NETs).
4170 Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of malignancies. Somato...
Exploiting ribosomal biogenesis dependence through RNA polymerase I inhibition in medulloblastoma.
e14106 Background: Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Despite multimodal therapy, hi...
Feasibility of an integrated aging assessment for cancer patients in oncology clinics.
e13593 Background: Older adults living with cancer navigate complex medical, psychosocial, and environmental needs – which...
Clinical and socioeconomic prognostic factors in chronic lymphocytic leukemia with normal FISH.
e19025 Background: Chronic lymphocytic leukemia (CLL) is the most common leukemia, with an estimated 23,690 new cases in 2...
Characterization and management of gastrointestinal (GI) adverse events (AEs) with zanidatamab + chemotherapy (CT) ± tislelizumab in first-line (1L) HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (mGEA): Analysis from HERIZON-GEA-01.
4042 Background: In HERIZON-GEA-01, replacing 1L trastuzumab (tras) + CT with zanidatamab + CT ± tislelizumab significantl...
First-in-class Trop2-targeted PET imaging with <sup>68</sup> Ga-MY6349 for diagnostic accuracy and altered management in recurrent/metastatic thyroid cancer compared to standard <sup>18</sup> F-FDG PET/CT.
6041 Background: Accurate, non-invasive detection of recurrent and metastatic thyroid cancer remains an unmet clinical nee...
Later-line treatment of PD-1 and CTLA-4 blockade combined with liposomal irinotecan plus leucovorin and fluorouracil for advanced biliary tract cancer: A prospective, phase 2 trial.
e16178 Background: For advanced biliary tract cancer (BTC) patients who failed first-line chemotherapy, second-line option...
Comparison of prophylactic effects for chemotherapy-induced neutropenia between same-day versus next-day administration of pegteograstim in chemotherapy regimen composed of day 1 intensive myleosuppressive agent: A randomized clinical trial (CONCISE, KCSG PC22-11).
12126 Background: Same-day administration of pegylated G-CSF is frequently used in clinical practice despite guideline rec...
The role of GPD1L in colorectal cancer progression: A systematic review of its expression, molecular mechanisms, and prognostic significance.
e15728 Background: Colorectal cancer (CRC) continues to be one of the leading causes of cancer-associated morbidity and mo...
A systematic review and meta-analysis on safety and efficacy of Lu-177 PSMA-617 and standardized treatment in mCRPC from randomized phase II/III trials.
e17069 Background: Lu-177 PSMA-617 delivers targeted β-radiation to prostate cancer cells, offering a distinct mechanism b...
Comparative real-world safety of nivolumab versus pembrolizumab in malignant melanoma: A propensity-matched cohort study.
e21587 Background: Nivolumab and pembrolizumab are widely used programmed cell death-1 (PD-1) inhibitors approved for the...
Longitudinal immune programs and association with toxicity burden and antitumor response during immunotherapy.
2541 Background: Immune-related adverse events (irAEs) and tumor responses often co-occur during immune checkpoint inhibit...